technology development

The two firms are collaborating on a system to share genotypic, phenotypic, and treatment outcomes data with physicians on a mobile-device network.

The partners will work to develop and distribute IROA Technologies' kit for chemically labeling metabolites for mass spectrometry analysis.

As part of the agreement, the organizations will develop a joint Seattle-Shenzhen Institute. 

The tools the partners plan to develop will help researchers optimize genomic analysis workflows and better identify links between genes and disease.

The partners will develop a new product using MBio's multiplex, point-of-care testing system and Roka's experience in food safety testing.

The companies will collaborate on a test to evaluate programmed death-ligand 1 protein expression levels in tumor tissue and its microenvironment.

The innovation hub will be fully operational by end of 2016 or in early 2017 and will be headquartered in the Cambridge Biomedical Campus.